• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[冠状动脉Palmaz-Schatz支架植入后抗凝血酶III、凝血酶原片段1+2及凝血酶-抗凝血酶III复合物的变化]

[Changes in antithrombin III, prothrombin fragment 1 + 2 and thrombin-antithrombin III complex following implantation of a coronary Palmaz-Schatz stent].

作者信息

Dittel M, Haushofer A, Spiel R, Halbmayer W M, Prachar H, Fischer M, Mlczoch J

机构信息

Medizinische Abteilung mit Kardiologie, Krankenhaus Lainz, Ludwig-Boltzmann-Institut für Herzinfarktforschung, Wien, Osterreich.

出版信息

Z Kardiol. 1995 Jan;84(1):22-9.

PMID:7863710
Abstract

To detect changes in the clotting parameters antithrombin III (AT III), prothrombin-fragment 1 + 2 (F 1 + 2) and thrombin-antithrombin-III-complex (TAT) after implantation of Palmaz Schatz stents, coagulation was monitored at standardized time points in 35 patients for 10 days. All patients were anticoagulated using a combination of heparin, phenprocoumon, and acetyl salicylic acid. Heparin therapy was guided by APTT levels (normal range 25-35 s), which were still within the therapeutic range (median 49.6 s (25%/75% percentiles 41.6/54.4) on day 10. Simultaneous oral anticoagulation was found to be effective on day 8 on average (INR median 2.24 (1.93/2.50)). The AT III activity dropped significantly (p < 0.0001) after a heparin loading dose of 15,000 IU during stenting. As the heparin dose was reduced on the following days, AT III levels increased significantly (p < 0.0001) during the observation time. There was a highly significant (p < 0.001) negative correlation between AT III and heparin levels. On days 4 and 5 F 1 + 2 values were significantly (p < 0.001 and p < 0.05) higher than on the day of stenting (median 1.07 (0.90/1.31) 1.13 nmol/l and 1.06 (0.85/1.23) nmol/l vs. 0.97 (0.69/1.15) nmol/l) and dropped during anticoagulation. F 1 + 2 levels showed a significant negative correlation (p < 0.0005) with APTT values. TAT values showed no significant changes during the observation period.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

为检测Palmaz Schatz支架植入后凝血参数抗凝血酶III(AT III)、凝血酶原片段1+2(F 1+2)和凝血酶-抗凝血酶III复合物(TAT)的变化,在35例患者中于标准化时间点监测凝血情况,持续10天。所有患者均联合使用肝素、苯丙香豆素和乙酰水杨酸进行抗凝治疗。肝素治疗以活化部分凝血活酶时间(APTT)水平(正常范围25 - 35秒)为指导,在第10天时其仍处于治疗范围内(中位数49.6秒(第25/75百分位数41.6/54.4))。同时口服抗凝治疗平均在第8天起效(国际标准化比值(INR)中位数2.24(1.93/2.50))。在支架置入期间给予15,000 IU肝素负荷剂量后,AT III活性显著下降(p < 0.0001)。在接下来的几天中,随着肝素剂量减少,观察期间AT III水平显著升高(p < 0.0001)。AT III与肝素水平之间存在高度显著的负相关(p < 0.001)。在第4天和第5天,F 1+2值显著高于支架置入当天(p < 0.001和p < 0.05)(中位数分别为1.07(0.9 / 1.31)、1.13 nmol/l和1.06(0.85 / 1.23)nmol/l,而支架置入当天为0.97(0.69 / 1.15)nmol/l),且在抗凝过程中下降。F 1+2水平与APTT值呈显著负相关(p < 0.0005)。在观察期内TAT值无显著变化。(摘要截选至250词)

相似文献

1
[Changes in antithrombin III, prothrombin fragment 1 + 2 and thrombin-antithrombin III complex following implantation of a coronary Palmaz-Schatz stent].[冠状动脉Palmaz-Schatz支架植入后抗凝血酶III、凝血酶原片段1+2及凝血酶-抗凝血酶III复合物的变化]
Z Kardiol. 1995 Jan;84(1):22-9.
2
Course of thrombin activation markers in patients implanted with Palmaz-Schatz stents: first experiences with a post-interventional anticoagulation regimen.
Blood Coagul Fibrinolysis. 1994 Oct;5(5):697-706. doi: 10.1097/00001721-199410000-00004.
3
[Prothrombin fragment 1+2 (F1+2), thrombin-antithrombin III complex(TAT) and thrombophilia parameters in orally anticoagulated patients with inferior vena cava filters].口服抗凝治疗的下腔静脉滤器置入患者的凝血酶原片段1+2(F1+2)、凝血酶-抗凝血酶III复合物(TAT)及血栓形成倾向参数
Wien Med Wochenschr. 1993;143(5):95-8.
4
Influence of long term oral anticoagulants upon prothrombin fragment 1 + 2, thrombin-antithrombin III complex and D-Dimer levels in patients affected by proximal deep vein thrombosis.长期口服抗凝剂对近端深静脉血栓形成患者凝血酶原片段1+2、凝血酶-抗凝血酶III复合物及D-二聚体水平的影响
Thromb Haemost. 1993 Apr 1;69(4):302-5.
5
Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.体外自凝全血中的凝血酶原片段1+2、凝血酶-抗凝血酶III复合物及纤维蛋白肽A。添加肝素及抗凝血酶III缺乏的影响。
Thromb Haemost. 1994 Jan;71(1):49-53.
6
Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.依诺肝素与普通肝素对非ST段抬高型急性冠状动脉综合征凝血酶生成的比较
Thromb Haemost. 2001 Oct;86(4):991-4.
7
Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer.妇科癌症患者血浆中凝血酶原片段F1+2和凝血酶-抗凝血酶III复合物(TAT)的水平
Gynecol Oncol. 1996 May;61(2):215-7. doi: 10.1006/gyno.1996.0127.
8
Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis.
Thromb Haemost. 1993 Oct 18;70(4):550-3.
9
Guidance of anticoagulation after intracoronary implantation of Palmaz-Schatz stents by monitoring prothrombin and prothrombin fragment 1 + 2.
Am Heart J. 1995 Aug;130(2):228-38. doi: 10.1016/0002-8703(95)90433-6.
10
Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.在不稳定型心绞痛和非ST段抬高型心肌梗死患者中停用重组水蛭素和普通肝素输注后凝血功能的再激活:一项随机试验的结果。OASIS试点研究调查人员。缺血综合征评估策略组织。
Eur Heart J. 2000 Sep;21(17):1473-81. doi: 10.1053/euhj.1999.2005.